Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?

被引:10
作者
Castelli, Joel [1 ,2 ]
Depeursinge, Adrien [4 ,5 ]
de Bari, Berardino [1 ,6 ]
Devillers, Anne [7 ]
de Crevoisier, Renaud [2 ,3 ,8 ]
Bourhis, Jean [1 ]
Prior, John O. [9 ]
机构
[1] Lausanne Univ Hosp, Dept Radiat Oncol, Lausanne, Switzerland
[2] INSERM, U1099, Rennes, France
[3] Univ Rennes 1, LTSI, Rennes, France
[4] Ecole Polytech Fed Lausanne, Lausanne, Switzerland
[5] Univ Appl Sci Western Switzerland, Sierre, Switzerland
[6] Univ Hosp Jean Minjoz, INSERM 1098, Besancon, France
[7] Ctr Eugene Marquis, Nucl Med Dept, Rennes, France
[8] Ctr Eugene Marquis, Dept Radiat Oncol, Ave Bataille Flandre Dunkerque, F-35000 Rennes, France
[9] Lausanne Univ Hosp, Nucl Med & Mol Imaging Dept, Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
metabolic tumor volume; oropharyngeal cancer; PET; threshold; SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; NECK-CANCER; PROGNOSTIC VALUE; CONCOMITANT CHEMOTHERAPY; RADIATION-THERAPY; F-18-FDG PET/CT; ADVANCED HEAD; CHEMORADIOTHERAPY; RECOMMENDATIONS;
D O I
10.1097/RLU.0000000000001614
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose In the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival. Methods One hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods: (i) an absolute threshold of SUV (0-20 g/mL) or (ii) a relative threshold for SUVmax (0%-100%). The parameters' predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model. Results Relative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], P = 0.009) and LRC (hazard ratio: 1.22 [per 10 mL], P = 0.02). Conclusions The use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.
引用
收藏
页码:e281 / e285
页数:5
相关论文
共 33 条
  • [1] Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase 18FDG PET-CT imaging in patients with head and neck cancer
    Abgral, Ronan
    Valette, Gerald
    Robin, Philippe
    Rousset, Jean
    Keromnes, Nathalie
    Le Roux, Pierre-Yves
    Marianowski, Remi
    Salauen, Pierre-Yves
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E600 - E606
  • [2] Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma
    Abgral, Ronan
    Keromnes, Nathalie
    Robin, Philippe
    Le Roux, Pierre-Yves
    Bourhis, David
    Palard, Xavier
    Rousset, Jean
    Valette, Gerald
    Marianowski, Remi
    Salauen, Pierre-Yves
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (04) : 659 - 667
  • [3] Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
    Bernier, J
    Domenge, C
    Ozsahin, M
    Matuszewska, K
    Lefèbvre, JL
    Greiner, RH
    Giralt, J
    Maingon, P
    Rolland, F
    Bolla, M
    Cognetti, F
    Bourhis, J
    Kirkpatrick, A
    van Glabbeke, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) : 1945 - 1952
  • [4] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    Bonner, James A.
    Harari, Paul M.
    Giralt, Jordi
    Cohen, Roger B.
    Jones, Christopher U.
    Sur, Ranjan K.
    Raben, David
    Baselga, Jose
    Spencer, Sharon A.
    Zhu, Junming
    Youssoufian, Hagop
    Rowinsky, Eric K.
    Ang, K. Kian
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 21 - 28
  • [5] Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
    Bourhis, Jean
    Sire, Christian
    Graff, Pierre
    Gregoire, Vincent
    Maingon, Philippe
    Calais, Gilles
    Gery, Bernard
    Martin, Laurent
    Alfonsi, Marc
    Desprez, Patrick
    Pignon, Thierry
    Bardet, Etienne
    Rives, Michel
    Geoffrois, Lionel
    Daly-Schveitzer, Nicolas
    Sen, Sok
    Tuchais, Claude
    Dupuis, Olivier
    Guerif, Stephane
    Lapeyre, Michel
    Favrel, Veronique
    Hamoir, Marc
    Lusinchi, Antoine
    Temam, Stephane
    Pinna, Antonella
    Tao, Yun Gan
    Blanchard, Pierre
    Auperin, Anne
    [J]. LANCET ONCOLOGY, 2012, 13 (02) : 145 - 153
  • [6] Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist
    Cacicedo, Jon
    Navarro, Arturo
    del Hoyo, Olga
    Gomez-Iturriaga, Alfonso
    Along, Filippo
    Medina, Jose A.
    Elicin, Olgun
    Skanjeti, Andrea
    Giammarile, Francesco
    Bilbao, Pedro
    Casquero, Francisco
    de Bari, Berardino
    Dal Pra, Alan
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1067)
  • [7] A Nomogram to predict parotid gland overdose in head and neck IMRT
    Castelli, J.
    Simon, A.
    Rigaud, B.
    Lafond, C.
    Chajon, E.
    Ospina, J. D.
    Haigron, P.
    Laguerre, B.
    Loubiere, A. Ruffier
    Benezery, K.
    de Crevoisier, R.
    [J]. RADIATION ONCOLOGY, 2016, 11
  • [8] Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer
    Cheng, Nai-Ming
    Fang, Yu-Hua Dean
    Lee, Li-yu
    Chang, Joseph Tung-Chieh
    Tsan, Din-Li
    Ng, Shu-Hang
    Wang, Hung-Ming
    Liao, Chun-Ta
    Yang, Lan-Yan
    Hsu, Ching-Han
    Yen, Tzu-Chen
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (03) : 419 - 428
  • [9] Metabolic tumour volume Prognostic value in locally advanced squamous cell carcinoma of the head and neck
    Deron, P.
    Mertens, K.
    Goethals, I.
    Rottey, S.
    Duprez, F.
    De Neve, W.
    Vermeersch, H.
    Van de Wiele, C.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2011, 50 (04): : 141 - 146
  • [10] Recommendations on the use of 18F-FDG PET in oncology
    Fletcher, James W.
    Djulbegovic, Benjamin
    Soares, Heloisa P.
    Siegel, Barry A.
    Lowe, Val J.
    Lyman, Gary H.
    Coleman, R. Edward
    Wahl, Richard
    Paschold, John Christopher
    Avrill, Norbert
    Einhorn, Lawrence H.
    Suh, W. Warren
    Samson'O, David
    Delbekell, Dominique
    Gorman, Mark
    Shields, Anthony F.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (03) : 480 - 508